You are here


Clinical Development of VRC programs with the industry

Two preclinical projetcs of the VRC, anti-PlGF for the treatment of cancer and eye disease, and VEGF treatment for ALS, are currently being developed for clinical use together with biotech companies. Clinical trials for both programs are being planned and will likely start before the end of the year.

Development of anti-PIGF for treatment of cancer and eye disease

Markers of response for the anti-angiogenic agent bevacizumab

Development of VEGF treatment for ALS

Development of anti-PIGF for treatment of cancer and eye disease



Karen Vousden, Paolo Sassone-Corsi, Christian Frezza, Nika Danial
12/09/2017 - 09:00